FDA accepts NDA for XP12B, a treatment for menorrhagia - MPR
Links shared publicly online about this topic.
- 2,144total visits
FDA accepts NDA for XP12B, a treatment for menorrhagia - MPR
empr.com —
Xanodyne Pharmaceuticals announced that the FDA has accepted for filing and granted priority review for the New Drug Application (NDA) submitted for XP12B (tranexamic acid).
View full resource at empr.com
Tags: Hemophilia Medication, Drug, Pharma, FDA, Cyklokapron, News
Most Recently Shared on April 2, 2009 at 10:38 pm By:
MPR News: FDA accepts NDA for XP12B, a treatment for menorrhagia: Xanodyne Pharmaceuticals announced th.. http://tinyurl.com/cphjh7
Advertisement
